Nature Biotechnology24, 737 - 739 (2006)
Published online: 6 July 2006; | doi:10.1038/nbt0706-737
Patently absurd?
Ken Garber
Ann Arbor, Michigan
Ariad Pharmaceuticals's victory against Lilly on NF-B patent infringement has drug companies and legal experts wondering about the future of biotech patenting. Ken Garber reports on the aftermath of the surprising decision.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
B patent infringement has drug companies and legal experts wondering about the future of biotech patenting. Ken Garber reports on the aftermath of the surprising decision.
